Part One: For the Motion. Carotid Endarterectomy is Safer than Stenting in the Hyperacute Period After Onset of Symptoms  by Naylor, A.R.
EDITORS’ INTRODUCTION
Trans-Atlantic Debate: Whether Carotid Endarterectomy is Safer than
Stenting in the Hyperacute Period After Onset of Symptoms
T.L. Forbes
Division of Vascular Surgery, University of Toronto, 200 Elizabeth St, Eaton North 6-222, Toronto, ON M5G2C4, Canada
The carotid artery has been a regular battleground for de-
bates regarding many issues, including appropriate man-
agement of symptomatic and asymptomatic lesions, the
conduct, timing and safety of such interventions, and now
whether endarterectomy or stenting is safer in the
hyperacute period. Our discussants agree that, as a pro-
phylactic procedure, a carotid intervention should occur
early after index symptoms to prevent as many strokes as
possible. However, which intervention is best?
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WHY ARE WE HAVING THIS DEBATE?
The updated 2014 American Heart Association (AHA)
guidelines advise that carotid endarterectomy (CEA) be
considered in patients presenting with a transient ischaemic
attack (TIA) or ischaemic stroke in the preceding 6 months,
and who have an ipsilateral 50e99% carotid stenosis, pro-
vided perioperative morbidity/mortality is < 6% (class I,
level of evidence A for 70e99% stenoses; class I, level of
evidence B for 50e69% stenoses).1 However, this “6-
month” threshold for intervening is a historical “quirk”
and has been retained within guidelines since the early
1990s. Rather than being based on evidence, it simply re-
ﬂects surgeon/neurologist equipoise relating to the time
period that was considered appropriate for randomizing
symptomatic patients within the international trials over
three decades ago.
Over the last 10 years, increasingly compelling evidence
suggests that the risk of stroke after suffering a TIA is very
much front loaded (rather than being evenly distributed
across the 6-month time period), with the highest-risk
period being the ﬁrst 14 days after onset of symptoms.
Thereafter, the beneﬁt conferred by CEA diminishes, and if
CEA is delayed by >12 weeks, only eight strokes will be
prevented at 5 years per 1,000 CEAs performed2; that is
992 of 1,000 patients receiving CEA will undergo an ulti-
mately unnecessary intervention From the historical
perspective, it is important to be aware that had the Eu-
ropean Carotid Surgery Trial (ECST) been dominated by
centres taking > 50 days to perform CEA (from symptom
onset), the ECST would not have shown signiﬁcant beneﬁt
favouring surgery.3 In a pooled series of > 500 patients
whose stroke was preceded by a TIA, 43% of strokes
happened within the ﬁrst 7 days of the index TIA,4 with a
third happening on the same day as the TIA. A meta-
analysis of data from the ECST, the North American
Symptomatic Carotid Endarterectomy Trial (NASCET), and
the Veterans Affairs (VA) trial has shown that CEA
conferred maximum beneﬁt (in terms of strokes prevented)
when undertaken within 14 days.2 This was particularly
evident in women, and the meta-analysis suggested that
few women beneﬁtted from CEA (even those with 70e99%
stenoses) if > 4 weeks had elapsed before undergoing
CEA.5 These data were responsible for guidelines by the
National Institute for Health and Care Excellence (2008) and
the European Society of Vascular Surgery (2009) advising
that CEA should be performed within 14 days of the index
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symptom.6,7 A similar (although slightly watered down)
recommendation has recently appeared in AHA guidelines.1
To complicate matters, a 2007 expert panel (commis-
sioned by the UK Department of Health) concluded that
patients with TIA should be treated as emergencies and
should undergo CEA at < 48 hours of symptom onset.8 At
the time, there was little evidence to support this recom-
mendation, but history has proved that it was closer to the
mark than expected. Table 1 details the early risk of stroke
(after an index TIA) in patients with a 50e99% carotid
stenosis in seven contemporary natural history studies. For
comparison, the 5-year risk of stroke in medically treated
patients with 50e99% stenoses randomized within ECST,
NASCET, and the VA trial is provided. At 5 years, the stroke
risk in medically treated patients in the randomized trials
was 21%. Note, however, that in the seven contemporary
natural history studies, the 14-day risk of stroke was the
same (or higher) than was observed at 5 years in the ran-
domized trials. Accordingly, what Table 1 shows is that (i)
the early risk of stroke is very much higher than previously
thought and (ii) very few of these really “high-risk” patients
were randomized within the international trials.9 The latter
cohort, therefore, represents a “lost tribe” and manage-
ment practices need to change in order that they can
undergo expedited/emergency interventions that can pre-
vent their stroke from happening.
WHY IS THE EARLY STROKE RISK SO HIGH?
In 1977, Harrison and Marshall showed that when CEA was
performed within 4 weeks of the index TIA, 66% of patients
had thrombus overlying their plaque compared with only
21% when CEA was performed thereafter.10 Surgeons who
have regularly been performing CEA within 7 days of
symptom onset increasingly encounter grossly disrupted
plaques with large amounts of overlying thrombus (Fig. 1),
which is associated with higher rates of spontaneous
embolization being detected on transcranial Doppler in the
early time period after symptom onset (42% prevalence at
< 7 days of symptom onset, 22% at 8e14 days, and 16% for
> 14 days).11 The high prevalence of overlying thrombus
and spontaneous embolization in this early time period
explains why patients admitted for emergency/expedited
CEA within 5 days of symptom onset face an 11e15% risk of
recurrent neurological events before getting to theatre.11,12
DO EARLY INTERVENTIONS NOT INCREASE PROCEDURAL
RISKS?
Rockman et al. reported that stroke rates after CEA were
signiﬁcantly higher (5.1%) when CEA was performed within
4 weeks of the presenting symptom compared with only
1.6% (p ¼ .02) when CEA was delayed beyond this time
period.13 Taken in conjunction with a historical perception
that the early risk of stroke after TIA is not unduly high,
augmented by the AHA retaining “6 months” as an
acceptable time threshold for intervening, it is perhaps not
surprising that a “comfort zone” has evolved where there is
little or no impetus to intervene early, especially if one is
also trying to work through the learning curve associated
with carotid artery stenting (CAS). Put simply, many ﬁnd it
easier to reassure themselves falsely that any potential
beneﬁt achieved through intervening early (in terms of late
stroke prevention) will be offset by the consequences of
increased procedural risks.
However, an alternative interpretation of the pooled
NASCET, ECST, and VA trial data suggests this is a disin-
genuous and potentially harmful assumption because the
surgeon or interventionist who performs CEA/CAS within 14
days with a 10% procedural risk will actually prevent more
strokes at 5 years than the surgeon/stenter who waits for 4
weeks and then operates with a 0% risk.14 Sometimes,
things are not always what they seem! Fortunately, the
need to balance the potential for increased procedural risks
against the beneﬁts of intervening early is being addressed
in the ongoing SPREAD-STACI trial, which is randomizing
patients to urgent CEA (< 48 hours) and delayed CEA (48
hours to 15 days) after symptom onset.15
THE AHA STATES THAT CAS IS NOW AN ALTERNATIVE TO
CEA
In the updated 2014 guidelines, the AHA reafﬁrmed that
CAS was now an alternative to CEA in symptomatic patients
Table 1. Risk of stroke in the hyperacute period after the index
transient ischemic attack in patients with 50e99% carotid
stenosis compared with pooled data from the randomized trials.a
48 h 72 h 7 d 14 d 5 y
ESCT þ NASCET þ VA
(medical therapy)2
21%
Fairhead et al. (2005)29 20%
Purroy et al. (2007)30 10%
Ois et al. (2009)31 17% 22% 25%
Bonifati et al. (2011)32 8%
Johansson et al. (2013)33 5% 8% 11%
Merwick et al. (2013)34 8%
Marnane et al. (2014)35 5% 9% 9% 16%b
Note.
a Reproduced with permission from Naylor et al.8
b Additional data provided by authors (personal communication).
Figure 1. Carotid endarterectomy (CEA) specimen shows disrupted
plaque with large amounts of overlying thrombus.
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with 50e99% stenoses, who were considered to be at
average or low risk of suffering complications.1 In the 2011
AHA guidelines, CAS was accorded a “class I, level of evi-
dence B” recommendation, but the 2014 guidelines down-
graded this to “class IIa, level B”.1 However, despite having
indicated that CAS was an alternative to CEA, and that
intervening within 2 weeks was “reasonable” unless con-
traindicated, the AHA provided no speciﬁc guidance on
which intervention was more appropriate in the hyperacute
period after onset of symptoms. This is important (espe-
cially for less experienced practitioners), as intervening
within 2 weeks of symptom onset (and especially within 7
days) means that the patient is highly likely to have a pla-
que with overlying thrombus present.
PROCEDURAL RISKS AFTER CEA AND CAS
There is a paucity of quality data on procedural risks after
stenting and surgery when performed in the ﬁrst 14 days
after onset of symptoms. Table 2 details CEA outcomes from
three relatively large published series. The “stand-out” sta-
tistic was the 11.5% death/stroke rate at 30 days when CEA
was performed within < 48 hours of symptom onset in the
SwedVasc Registry.16 Thereafter, CEA was performed with
procedural risks < 5%. The Leicester group reported out-
comes in 475 patients undergoing expedited CEA.17 Unlike
SwedVasc, the Leicester group observed no excess proce-
dural risk when CEA was performed within 48 hours (2.4%),
and this ﬁnding was corroborated in the largest of the three
studies, where Rantner et al. reported a 4.4% death/stroke
rate in 206 patients in whom CEA was performed within 48
hours of symptom onset.18 Finally, the latest national report
from the UK CEA Audit observed that 1,611 patients un-
derwent CEA within 7 days of symptom onset, with a 2.7%
death/stroke rate at 30 days,19 suggesting that the majority
of patients (nationally) can safely undergo CEA in the hy-
peracute period.
By contrast, most studies suggest that performing CAS
within 14 days is associated with excess procedural risks.
One key exception was shown by Moratto et al.,20 who
reported 30-day death/stroke rates of 2.6% when protected
CAS was performed within 48 hours of symptom onset and
(to date) these are the best in the published literature. By
contrast, however, the CAPTURE Registry concluded that
the time interval between the qualifying neurological
symptom and undergoing CAS was predictive of outcome.21
Patients undergoing protected CAS within 14 days of
suffering a stroke/TIA were signiﬁcantly more likely to suffer
a procedure-related stroke (odds ratio 2.5, 95% conﬁdence
interval 1.3e4.8). In a series of 77 recently symptomatic
patients, Topakian et al. also observed that patients un-
dergoing protected CAS within 14 days of symptom onset
faced a signiﬁcantly higher procedural risk (26% vs. 1.9%),22
although an association between recency of symptoms and
increased procedural risk was disputed by Groschel et al.23
In the latter study, the 30-day death/stroke rate was no
different when CAS was performed within 14 days of
symptoms (7.0%) compared with any time thereafter
(9.6%).
The largest study to compare outcomes in the hyperacute
period after onset of symptoms comes from a meta-analysis
of the three European randomized trials. Patients under-
going CAS within 7 days of symptom onset faced a threefold
excess risk of death/stroke (9.4%) compared with patients
undergoing CEA during the same time period (2.8%;
p ¼ .03).24 A similar excess procedural risk persisted when
procedures were performed 8e14 days after symptom
onset (8.1% CAS vs. 3.4% after CEA; p ¼ .04). The European
randomized trials have been heavily criticized (regarding
interventionist experience),25 despite the fact that the most
experienced stenters in the French Endarterectomy Versus
Angioplasty in Patients with Symptomatic Severe Carotid
Stenosis (EVA-3S) trial incurred the highest rates of proce-
dural stroke/death (10.5%), while the most experienced
stenting centres in the International Carotid Stenting Study
(ICSS) reported higher procedural risks (8.7%) than their less
experienced counterparts (6.9%).26 More importantly, the
8e9% procedural risk in the (much viliﬁed) European ran-
domized trials when CAS was performed within 14 days is
actually no different to the 8.8% procedural risk reported in
the US Cordis Carotid Stent Collaborative, where patients
underwent protected CAS within 14 days of symptom
onset.27
Of course, new CAS innovations await evaluation, most
notably the newer ﬂow reversal protection systems, as well
as membranous stents. However, no one has published
outcome data stratiﬁed for recency of symptoms with these
newer technologies. The simple fact is that most registry
cohorts that are recruited to evaluate these newer in-
novations are dominated by the inclusion of asymptomatic
patients. It is essential that procedural risks are stratiﬁed for
recency of symptoms and reported in any future
publication.
The key question for the future will, of course, relate to
generalizability into routine practice rather than using the
excellent (isolated) studies from Moratto and colleagues
and a few others to justify practice. In that respect, two
large US registries have published data in 2014 and provide
worrying evidence that CAS is still some way off from being
safely adopted by the majority of CAS practitioners for the
majority of symptomatic patients (i.e., real-world practice is
not matching trial outcomes). In a series of 1,753 patients
who had reported symptoms within the preceding 6
Table 2. Thirty-day death/stroke after carotid endarterectomy stratiﬁed for delay from index symptom to surgery.
0e48 h 3e7 d 8e14 d >14 d
Stromberg et al. (2012)15 17/148 (11.5%) 29/894 (3.6%) 26/677 (4.0%) 52/967 (5.4%)
Sharpe et al. (2013)16 1/41 (2.4%) 3/167 (1.8%) 1/133 (0.8%) 1/134 (0.7%)
Rantner et al. (2015)17 9/206 (4.4%) 4/219 (1.8%) 6/136 (4.4%) 5/200 (2.5%)
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months (never mind 14 days), the National Hospital
Discharge Database reported a 10% death/stroke rate at 30
days following protected CAS.28 However, this very high
procedural risk was exceeded by a larger registry, which
reported a 12.8% death/stroke rate in 10,177 patients who
reported symptoms within the preceding 6 months and
who underwent protected CAS in the Nationwide Inpatient
Sample database.29
There is no doubt that CAS has evolved considerably over
the last two decades but, for now, CEA remains safer than
stenting (for the majority of patients) in the hyperacute
period after onset of symptoms.
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EARLY RISK OF RECURRENT STROKE AFTER TRANSIENT
ISCHEMIC ATTACK/MINOR STROKE
The most commonly quoted risk of 1e2% at 1 week and 4%
at 1 month are considered to be underestimated because
patients are generally seen several weeks after a transient
ischemic attack (TIA) or minor stroke.1,2 In a study of pa-
tients presenting to the emergency department within 24 h
of a TIA, Johnston et al. reported a risk of stroke of around
5% at 2 days.3 Coull et al. reported on early risk of stroke
after TIA/minor stroke, and found that the risk of recurrent
stroke was 8.0% at 1 week, 11.5% at 1 month, and 17.3% at
3 months, and after a minor stroke they were 11.5%, 15.0%,
and 18.5%, respectively.4 This is critical, as the beneﬁt from
carotid intervention (carotid endarterectomy or stenting)
falls rapidly with time after a TIA/minor stroke.4 Several
other authorities have reported that the risk of recurrent
stroke after TIA/minor stroke is highest within the ﬁrst 7e
14 days in patients with carotid disease.5e8
Two recent meta-analyses showed that the risk of stroke
after TIA was 6.7% at 48 h and 10.0% at 1 week.7,8 Patients
with carotid artery stenosis showed the highest rate of
stroke after TIA (4.0% at 1 week, 12.6% at 30 days, and
19.2% at 3 months).9 Almost half of all strokes observed
within 1 week occur within the ﬁrst 24 h.10 Rothwell and
Warlow reported on a pooled cohort of 549 patients whose
stroke was preceded by a TIA;11 43% of the index TIAs were
observed within 1 week of the stroke, while 17% occurred
on the same day as the stroke.
Pooled data from the North American Symptomatic Ca-
rotid Endarterectomy Trial (NASCET) and the European Ca-
rotid Surgery Trial (ECST) showed that the beneﬁt from
carotid endarterectomy (CEA) depends on the time of CEA
after the index event and the degree of stenosis.12 Mono
et al. reported on the risk of early recurrent cerebrovascular
events in symptomatic carotid stenosis.13 Eighty-ﬁve pa-
tients underwent CEA and nine patients had carotid artery
stenting (CAS). The median time from the onset of symp-
toms to carotid intervention was 5 days. Twenty-one (22%)
patients underwent carotid intervention within 48 h of
being admitted. There were 15 (13%) recurrent cerebro-
vascular events in 12 patients in the period between
admission and carotid intervention: ﬁve TIAs (5.3%), one
amaurosis fugax (1.1%), and three strokes (3.2%) observed
within the ﬁrst 72 h (a total of 9.6%) of admissions. One TIA
(1.1%) occurred between 72 h and 1 week, and ﬁve TIAs
(5.3%) were noted after 1 week. The actuarial cerebrovas-
cular recurrence rates were 11.4% within 72 h of admission,
2.4% between 72 h and 1 week, and 7.9% after 1 week. The
rate of procedure-related cerebrovascular events was 4.3%.
Carotid intervention performed within the ﬁrst 48 h and
those performed after 48 h had similar outcomes.
Validation and reﬁnement of scores to predict very early
stroke risks after TIA was reported by Johnston et al.14 The
ABCD (age, blood pressure, clinical features, duration of TIA,
and diabetes) and California scoring systems were exten-
sively analyzed and validated cohorts consisting of 4,799
patients with TIAs, and renamed the ABCD2 score
(Table 1).14 As noted in Table 1, patients with a score of 3
have a very low stroke risk of 1.0% at 2 days, 1.2% at 1
week, and 3.1% at 3 months. Patients with a score of 4
were associated with an increased early stroke risk, with the
greatest risk being noticed in patients with a score of 6e7,
where the risk of stroke was 8.1% at 2 days, 11.7% at 1
week, and 17.8% at 3 months. Accordingly, the UK National
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